Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy

Trial Profile

Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2018

At a glance

  • Drugs Everolimus (Primary) ; Fulvestrant
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Aug 2018 Results of pooled analysis from 28 studies published in the Targeted Oncology
    • 17 Apr 2018 Primary endpoint (Progression-free survival)has been met, as per the results published in the Journal of Clinical Oncology.
    • 17 Apr 2018 Results assessing the effect of everolimus plus fulvestrant versus fulvestrant alone in postmenopausal women with ER-positive breast cancer published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top